The aim of this retrospective study was to investigate the safety and efficacy of Oxcarbazepine (OXC) in monotherapy in patients with brain tumour and epilepsy. We studied 21 patients; in 8 patients OXC was the first therapeutic choice, in 13 it substituted the first therapy. Oxcarbazepine induced no side effects. OXC induced a complete seizures control in 14 patients, a seizures rate reduction higher than 50% in 4 patients, an unmodified seizures rate in 2 patients. These preliminary data seem to indicate that OXC treatment in patients with brain tumours is quite safe and effective.
|Translated title of the contribution||Efficacy and tolerability of Oxcarbazepine in brain tumours and epilepsy|
|Number of pages||2|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - Jul 2006|
ASJC Scopus subject areas
- Clinical Neurology